What question did this study set out to answer?

To review the epidemiology, distinct and shared molecular pathogenesis, screening challenges, and current clinical management strategies for hepatocellular carcinoma arising from steatohepatitis and alcohol-related liver disease.

June 25, 2025BioChemOpen Access

HCC in MASLD and ALD: Biochemical Pathways, Epidemiology, Diagnosis, and Treatment

View Full Paper

Ask AI

Bookmark

Authors

SPSheel PatelChelsea and Westminster Hospital NHS Foundation Trust FKFares Kasem DFDylan FlahertyUniversity of Louisville

Discussion

Member takes

Implication

Review reveals distinct molecular drivers of hepatocellular carcinoma in metabolic and alcohol-related liver diseases, highlighting gaps in non-cirrhotic cancer screening and targeted therapy.

Key Points

To review the epidemiology, distinct and shared molecular pathogenesis, screening challenges, and current clinical management strategies for hepatocellular carcinoma arising from steatohepatitis and alcohol-related liver disease.
Narrative synthesis of clinical and experimental literature regarding metabolic and alcohol-induced liver carcinogenesis.
Evaluation of diagnostic tools including transient elastography and noninvasive fibrosis scoring alongside systemic, surgical, and locoregional therapies.
Metabolic-associated liver cancer is driven by insulin resistance, lipotoxicity, and PNPLA3 or TM6SF2 variants, whereas alcohol-associated malignancy is driven by acetaldehyde toxicity and oxidative stress.
Both etiologies share pathogenic drivers including intestinal permeability, gut dysbiosis, and immune dysregulation.
Established surveillance guidelines address cirrhotic liver disease effectively, but clinical consensus is currently lacking for screening non-cirrhotic steatohepatitis patients who remain vulnerable to cancer.

Cite This Study

Patel et al. (2025) studied this question.

synapsesocial.com/papers/6a12074e86b31d97fdb4cf7f https://doi.org/10.3390/biochem5030019

View Full Paper

Ask AI

Bookmark

Implication

Review reveals distinct molecular drivers of hepatocellular carcinoma in metabolic and alcohol-related liver diseases, highlighting gaps in non-cirrhotic cancer screening and targeted therapy.

HCC in MASLD and ALD: Biochemical Pathways, Epidemiology, Diagnosis, and Treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

HCC in MASLD and ALD: Biochemical Pathways, Epidemiology, Diagnosis, and Treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider